Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metronomic Cyclophosphamide and Dexamethasone in mCRPC
NCT05479578Phase 1Active, not recruiting
- Start
- Jun 2022
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoints: Feasibility of combination treatment up to 4 years and Incidence of adverse events up to 4 years. Started Jun 2022; status: active, not recruiting.
02
Drugs
cyclophosphamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT05479578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479578.